Two weeks later, the results of the patient&;s prenatal labs come back. Her blood type is A, with an antl D antibody titer of 1:4. What Is the most appropriate next step In the management of this patient?
**Core Concept**
The patient's high anti-D antibody titer indicates sensitization to Rh-positive blood, putting her at risk for hemolytic disease of the newborn (HDN) if she carries an Rh-positive fetus. The goal of management is to prevent fetal sensitization and reduce the risk of HDN.
**Why the Correct Answer is Right**
The most appropriate next step is to administer Rh immunoglobulin (RhIg) to the patient. RhIg is an immunoglobulin preparation that contains antibodies against RhD antigen. When administered to an Rh-negative mother, RhIg binds to any RhD antigen present on fetal red blood cells that may have crossed the placenta, preventing the mother's immune system from recognizing the antigen and mounting an immune response. This reduces the risk of sensitization and subsequent HDN in future pregnancies. RhIg should be administered between 28 and 30 weeks of gestation, and again within 72 hours of delivery if the patient has not received it previously.
**Why Each Wrong Option is Incorrect**
**Option A:** Administering corticosteroids to the patient is not relevant to the management of Rh sensitization, as it does not prevent the immune response to RhD antigen.
**Option B:** Performing a blood type and antibody screen on the patient's partner is not necessary, as the focus is on preventing fetal sensitization, not identifying the father's blood type.
**Option C:** Ordering a fetal ultrasound to assess fetal well-being is not directly relevant to the management of Rh sensitization, although it may be done to monitor fetal growth and detect any potential complications.
**Clinical Pearl / High-Yield Fact**
RhIg should be administered to all Rh-negative women between 28 and 30 weeks of gestation, regardless of their antibody titer, to prevent sensitization and reduce the risk of HDN.
**Correct Answer:** C. Rh immunoglobulin (RhIg) administration.